Veru is trading 5.02% up at $2.72, with biotech-sector momentum the strongest available explanation; no new company-specific announcement was identified on August 25, 2026.
- The XBI biotech ETF is up 2.06% during regular trading, supported by a broader market rally and positive biotechnology sentiment.
- Veru’s latest major updates—Q3 results, PLATEAU enrollment, and patent allowance—were announced earlier in August, not today.